Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:CLSNNASDAQ:FCSCNASDAQ:PULM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.85-0.5%$2.30$1.66▼$5.50$10.45M1.0210,530 shs13,382 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/APULMPulmatrix$1.75+8.0%$1.80$1.55▼$3.15$6.39M0.9517,331 shs38,150 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-3.23%-5.25%-19.64%-40.00%-52.43%CLSNImunon0.00%0.00%0.00%0.00%0.00%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%PULMPulmatrix-3.59%-1.07%-16.41%-15.98%-46.20%A lot of people are making this costly mistake (Ad)You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next oneMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix2.7928 of 5 stars3.55.00.00.03.30.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00471.43% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.48 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00FCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06PULMPulmatrix$6.07M1.05N/AN/A$8.55 per share0.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.75MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AFCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/APULMPulmatrix-$18.84M-$4.43N/A∞N/A-238.89%-64.09%-44.78%4/4/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A1.56N/ACLSNImunon0.136.526.52FCSCFibrocell Science0.475.095.09PULMPulmatrixN/A5.245.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CLSNImunon12.97%FCSCFibrocell Science36.72%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%CLSNImunon4.66%FCSCFibrocell Science1.10%PULMPulmatrix3.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics155.65 million2.16 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionablePULMPulmatrix283.65 million3.52 millionNot OptionableCLSN, FCSC, PULM, and AKTX HeadlinesSourceHeadlinePulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 28 at 11:46 AMPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updateprnewswire.com - March 28 at 9:05 AMPulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.comamericanbankingnews.com - March 23 at 2:16 AMCipla Ltd CIPLAmorningstar.com - February 15 at 11:00 PMGlobal deaths from fungal disease have doubled in a decade – new studytheconversation.com - January 13 at 7:42 AMFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersbizjournals.com - January 10 at 7:51 AMPulmatrix shuts down study, explores salebizjournals.com - January 9 at 3:43 PMPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Studynasdaq.com - January 8 at 1:11 PMPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternativesmarketwatch.com - January 8 at 1:11 PMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternativesfinance.yahoo.com - January 8 at 1:11 PMStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steelmsn.com - January 8 at 12:42 AMStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focusmsn.com - January 8 at 12:42 AMTrade Setup for Jan 8: IT earnings to be the Nifty 50's focal point this weekcnbctv18.com - January 7 at 9:11 AMPulmatrix Inc PULMmorningstar.com - November 12 at 9:08 AMPulmatrix Down on Q3 Resultsbaystreet.ca - November 9 at 1:38 PMPulmatrix GAAP EPS of -$1.03, revenue of $1.75Mmsn.com - November 9 at 1:38 PMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 1:38 PMAspergillosis Treatment Research Report 2023finance.yahoo.com - October 23 at 3:27 PMPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100markets.businessinsider.com - September 19 at 9:49 AMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migrainefinance.yahoo.com - September 19 at 9:49 AMPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowmsn.com - September 11 at 3:15 PMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazolefinance.yahoo.com - August 23 at 6:11 PMPulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 10 at 2:43 PMPulmatrix GAAP EPS of -$1.04, revenue of $1.84Mmsn.com - August 10 at 2:43 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.